Cardiac Adverse Events after Vaccination—A Systematic Review

Kanak Parmar 1,*, Sai Subramanyam 2, Gaspar Del Rio-Pertuz 1, Pooja Sethi 3 and Erwin Argueta-Sosa 3

1 Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; gaspar.del-rio-pertuz@ttuhsc.edu
2 School of Medicine, Vydehi Institute of Medical Sciences and Research Centre, Bangalore 560048, India; saiptp999@gmail.com
3 Department of Cardiovascular Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; pooja.sethi@ttuhsc.edu (P.S.); erwinargueta.sosa@ttuhsc.edu (E.A.-S.)

* Correspondence: kanak.parmar@ttuhsc.edu

Abstract: The Vaccine Adverse Event Reporting System database has been used to report adverse events following several vaccines. We studied the patient population predisposed to such reactions and how these reactions differ with respect to the vaccine type. We searched the electronic databases PubMed, EMBASE, and Scopus up to 9 July 2021 for any study describing cardiac adverse events attributed to the vaccination. A total of 56 studies met the criteria comprising 340 patients. There were 20 studies describing cardiac adverse events following smallpox vaccination, 11 studies describing adverse events after influenza vaccination, and 18 studies describing adverse events after COVID-19 vaccination. There was a total of six studies describing cardiac adverse events after the pneumococcal vaccine, tetanus toxoid, cholera vaccine, and rabies vaccine. Adverse events following influenza vaccination occurred more commonly in older females within an average duration of four days from vaccination. Pericardial involvement was the most reported adverse event. Adverse events following COVID-19 vaccination happened at a mean age of 42.7 years, more commonly in males, and mostly after a second dose. Adverse events following smallpox vaccination occurred more commonly in younger males, with an average onset of symptoms from vaccination around 16.6 days. Adverse events were mostly myopericarditis; however, the acute coronary syndrome has been reported with some vaccines.

Keywords: myocarditis; vaccination; pericarditis; myocardial infarction; adverse events

1. Introduction

Vaccination has remained an integral part of primary care medicine for preventing common and life-threatening diseases for decades. Vaccination has been associated with minor injection site reactions, fever, fatigue, and lymphadenopathy; however, serious neurological and cardiac adverse events (AEs) have been known to occur [1]. The Vaccine Adverse Event Reporting System (VAERS), a passive surveillance database, provides information on reports of AEs after vaccination with approved vaccines in the United States (2). Through this passive reporting, the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration (FDA) conduct post-licensure vaccine safety monitoring [2]. A study on the VAERS database from 1990 to 2018 showed 0.1% (708) myopericarditis cases out of the 620,195 reports of possible adverse events to VAERS [3]. At the end of 2019, a novel coronavirus now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, China [4]. It rapidly spread, resulting in a global pandemic affecting 400 million people worldwide and has taken approximately 6 million lives till now. In order to fight this infection, there was an emergent authorization of several vaccines by the World Health Organization all over the world. Two of them are Coronavirus disease (COVID-19) mRNA vaccines: BNT162b2 (Pfizer-BioNTech COVID-19 vaccine) and mRNA-1273 (Moderna COVID-19 vaccine), three are adenoviral vector vaccines:
Ad26.COV2.S (Janssen COVID-19 vaccine, also referred to as the Johnson & Johnson vaccine) and AZD1222 (Oxford/AstraZeneca), Covishield (Oxford/AstraZeneca), and lastly, three are inactivated vaccines: Covaxin (Bharat Biotech), BBIBP-CorV (Sinopharm) and CoronaVac (Sinovac) [5]. Soon after, various reports of adverse events (AEs) from the COVID-19 vaccines emerged [6–9]. The aim of our review is to investigate the patient characteristics and provide an overview of the management for patients that develop AEs after vaccination.

2. Methods

2.1. Design

We conducted a systematic review with a priori selection and outcome criteria according to “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” guidelines. We registered the study protocol in Prospero with CRD42021267467. We searched the electronic databases PubMed, EMBASE, and Scopus. The search included articles published from inception up to 9 July 2021. The MeSH (Medical Subject Headings) search terms were “myocarditis” or “myocardium” or “pericardial” or “pericardium” or “acute myocardial injury” OR “acute coronary syndrome” OR “heart failure” OR “arrhythmia” OR “troponin” OR “ischemia” OR “acute myocardial infarction” OR “coronary events” OR “creatine kinase” OR “heart” AND “vaccine”.

We excluded studies involving patients below 18 years of age. We included a study if it described cardiac AEs associated with the vaccination. We excluded any animal studies. Our primary outcome was to see the cardiac AEs reported to any vaccination.

2.2. Study Selection

Two authors (KP and GDRP) independently reviewed the retrieved abstracts and assessed eligibility. The full-text review was conducted when either of the reviewers of the abstracts felt that the citations might meet inclusion criteria. Disagreement was resolved by the engagement of a third author (SS).

2.3. Data Extraction

Data from the included studies were independently extracted by three authors (KP, GDRP, SS). We extracted the following data: age, gender, comorbidities, vaccine type, vaccine dose, number of days after which the event happened, inflammatory markers, imaging, results of an endomyocardial biopsy, and treatment instituted.

3. Results

Overall, 7327 studies were found on the PubMed, Embase, and Scopus databases (Figure 1). After removing duplicates, 6095 studies were screened by title and abstract for any cardiac AEs after vaccination. A total of 267 studies qualified and were opened for a full-text review. A final selection of 56 studies was selected for adverse cardiac events after vaccination, with a total of 340 patients. Eleven studies described cardiac AEs following influenza vaccination [10–20], and 18 studies described cardiac AEs after COVID-19 vaccination [6–9,21–35]. There were 20 studies reporting cardiac AEs after smallpox vaccination [36–55]. Among other vaccines, there were two reports of cardiac AEs after pneumococcal vaccination [56,57], three reports of cardiac AEs after tetanus toxoid [58–60], one report following cholera vaccination [61], and one report following rabies vaccine [62].

The median age for developing cardiac AEs following vaccination was 43.79 ± 21.2 years. Most of the patients described were males (84%) and rest were females (Table 1).

A total of 34 patients were included in cardiac AEs following influenza vaccination, with the mean age of patients being 68.55 ± 18.23 years. Fifty-five percent of cases described were female. Myocarditis/pericarditis/myopericarditis developed in 29 patients, and Takotsubo cardiomyopathy was described in two cases. The average time of symptom onset from vaccination was 4.7 ± 4 days. Anti-inflammatory treatment was used in 66% of patients, and one patient required an extracorporeal membrane oxygenator. Steroids were used on one patient. All patients recovered (Table 2).
A total of 67 patients developed cardiac AEs following COVID-19 vaccination. Overall, 35 cases reported AEs after BNT162b2 (Pfizer), 26 cases developed cardiac AEs after mRNA-1273, four cases developed cardiac AEs after AZD1222, and two cases developed cardiac AEs after receiving CoronaVac and JNJ-78436735. The average age for these patients was 42.7 years (SD = 19.6), with 59 (88%) patients being male gender. Most patients (69.6%) developed a reaction after the second dose. Myocarditis/pericarditis/myopericarditis developed in 35 patients. Acute coronary syndrome (ACS) was described in six patients. There was one case of myocardial infarction (MI) with non-obstructive coronary arteries (MINOCA) and one stress-induced cardiomyopathy. The average time of symptom onset from vaccination was 2.34 days (SD = 1.83 days). Moreover, 15 cases received anti-inflammatory treatment, and the same number of patients received colchicine. All patients recovered except one (Table 3).

A total of 232 developed adverse events following smallpox vaccination with a mean age of 29.48 ± 8.9 years. Most of these AEs (82.75%) were described in male patients. Most patients (212) developed myocarditis/myopericarditis or pericarditis. Twenty-six patients had ACS, and there were two cases of arrhythmias. The average duration of symptom onset from the time of vaccination was 16.6 days (SD = 14). For treatment, nine cases described the use of NSAIDs, and three patients received colchicine. Most patients developed AE following the first dose, but 30 patients developed a reaction after the second dose. There were three cases with mortality. Endomyocardial biopsy (EMB) was performed in eight cases, and four cases had eosinophilic infiltration (Table 4).

Cardiac AEs were also described with the pneumococcal vaccine, mostly in the elderly age group. Myopericarditis was also reported with tetanus toxoid in three males with an average age of 25 years. All three patients recovered, and a biopsy in one case showed eosinophilic infiltration. There was also one case of ACS reported after a cholera vaccination and myocarditis after a rabies vaccination (Table 5).

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow diagram.
Table 1. Summary of Vaccine Related Cardiac Adverse Events.

| Vaccine Type            | No. of Studies | No. of Patients | Average Time of Symptom Onset from Vaccination (Days) | Mean Age (±SD) | Gender       | Types of Events                                                                 | Outcome                      |
|-------------------------|----------------|-----------------|-------------------------------------------------------|----------------|--------------|--------------------------------------------------------------------------------|-------------------------------|
| Influenza vaccine       | 11             | 34              | 4.77                                                  | 68.55 ± 18.23  | Males: 15    | Myocarditis: 2 Pericarditis: 27 Pericardial effusion: 2 Takotsubo: 2 Kounis syndrome: 1 | Recovery in all patients      |
|                         |                |                 |                                                       |                | Females: 19  | Myocarditis: 55 MI: 6                                                          |                               |
| COVID-19 vaccines.      |                |                 |                                                       |                |              | Acute myocardial injury: 1 Type 1 Kounis syndrome: 1 MINOCA: 1 Pericarditis: 2 | 1 death. Recovery in all other patients. |
| Subtype:               |                |                 |                                                       |                |              | Myocarditis: 75 Pericarditis: 7 Myopericarditis: 121 Ischemic events: 26 DCM: 2 |                               |
| J&J: 1                 | 18             | 67              | 2.34                                                  | 42.73 ± 19.6   | Males: 59    | Myocarditis: 55 Pericarditis: 7 Myopericarditis: 121 Ischemic events: 26 DCM: 2 |                               |
| Pfizer: 35             |                |                 |                                                       |                | Females: 8   | Acute myocardial injury: 1 Type 1 Kounis syndrome: 1 MINOCA: 1 Pericarditis: 2 |                               |
| Moderna: 26            |                |                 |                                                       |                |              | Myocarditis: 75 Pericarditis: 7 Myopericarditis: 121 Ischemic events: 26 DCM: 2 |                               |
| Covishield: 4          |                |                 |                                                       |                |              | Acute myocardial injury: 1 Type 1 Kounis syndrome: 1 MINOCA: 1 Pericarditis: 2 |                               |
| CoronaVac: 1           |                |                 |                                                       |                |              | Myocarditis: 75 Pericarditis: 7 Myopericarditis: 121 Ischemic events: 26 DCM: 2 |                               |
| Smallpox vaccine       | 20             | 232             | 16.68                                                 | 29.48 ± 8.97   | Males: 192   | Myocarditis: 75 Pericarditis: 7 Myopericarditis: 121 Ischemic events: 26 DCM: 2 | 1 death. Recovery in all other patients. |
|                         |                |                 |                                                       |                | Females: 29  | Trigeminy: 1 Ventricular tachycardia: 1 Myocarditis: 1, Pericardial effusion: 1 |                               |
|                         |                |                 |                                                       |                | NR: 11       | Myocarditis: 2 Myopericarditis: 1 Myocardial infarction: 1                      |                               |
| Pneumococcal Vaccine   | 2              | 2               | 18                                                    | 73.00 ± 2.8    | Females: 2   | Myocarditis: 2 Myopericarditis: 1 Myocardial infarction: 1                      | Recovery in all patients      |
|                         |                |                 |                                                       |                |              | Myocarditis: 2 Myopericarditis: 1 Myocardial infarction: 1                      |                               |
| Tetanus toxoid         | 3              | 3               | 3                                                     | 25.66 ± 6.8    | Males: 3     | Myocarditis: 2 Myopericarditis: 1 Myocardial infarction: 1                      | Recovery in all patients      |
| Cholera                | 1              | 1               | 6                                                     | 40             | Male: 1      | Myocarditis: 2 Myopericarditis: 1 Myocardial infarction: 1                      | Recovery                     |
| Rabies                 | 1              | 1               | NR                                                    | 58             | Male: 1      | Myocarditis: 2 Myopericarditis: 1 Myocardial infarction: 1                      | NR                           |

Abbreviations: NR, Not reported, No, number; SD, standard deviation; J&J: Johnson and Johnson vaccine; DCM, dilated cardiomyopathy.
Table 2. Adverse events after Influenza vaccination.

| Author, Year | Country | Type of Study | Number of Cases | Median Age | Gender | Patient Comorbidities | Event | Dose after Which Event Happened | Days after Vaccination Symptoms | Treatment | Outcome |
|--------------|---------|---------------|-----------------|------------|--------|-----------------------|-------|-------------------------------|---------------------------------|-----------|---------|
| Chuen-Der Kao et al., 2003 [10] | Taiwan | Case report | 1 | 68 | F | NR | Pericarditis | 1 | 14 | Plasmapheresis | R | N |
| Y J Kim et al., 2017 [11] | Korea | Case report | 1 | 27 | F | NR | Myocarditis 1: pericardial effusion on echo, 2: pericarditis | 1 | 3 | ECMO | R | N |
| De Meester et al., 2000 [13] | Belgium | Case Report | 2 | 75, 40 | M | 1: CKD, DM, smoker, 2: smoker, hyperlipidemia | Pericarditis | 1 | 4 | NSAIDs | R | N |
| Santoro et al., 2013 [14] | Italy | Case report | 1 | 78 | M | NR | TTC | 1 | 3 | Furosemide, ramipril, and bisoprolol | NA | R | N |
| Singh et al., 2013 [15] | Australia | Case report | 1 | 86 | F | None | Pericarditis & Myocarditis | 1 | 1 | NSAIDs | R | N |
| Streifer et al., 1981 [16] | Israel | Case report | 1 | 61 | M | None | Pericarditis | 1 | 7 | NSAIDs | R | N |
| Cheng et al., 2016 [17] | Canada | Case report | 1 | 65 | M | None | Pericardial effusion | 2 | 1st event: 5–7 days; 2nd event: few days; 3rd event: relapse: 8 months later | Prednisone pericardiocentesis | R | N |
| Mei et al., 2018 [12] | Italy | Case report | 1 | 87 | M | COPD, thyroidectomy, MI, total AV block with SSS | Pericardial effusion | 1 | 15 min | Nitroglycerin | R | N |
| Garcia et al., 2013 [20] | Spain | Case report | 1 | 69 | M | IHD | Kounis syndrome | 1 | 15 min | Nitroglycerin | R | N |
| Zanettini et al., 2003 [18] | Brazil | Case series | 23 | 40–59: 3; ≥ 60: 19 | 16 F, 7 M | Obesity: 10, smokers: 10, HTN: 3, IHD: 2, HLD: 6, mitral valveopathy: 13, HTN cardiomyopathy: 8, arrhythmias: 7, COPD: 3, MI: 1, hypothyroidism: 1 | Pericarditis | 1 | NA | 19 patients: NSAIDs | R | N |
| Godreuil et al., 1983 [19] | France | Case report | 1 | 87 | M | NR | Hemorrhagic pericarditis | 1 | NA | Surgical pericardiectomy, colchicine | R | N |

MI, myocardial infarction; TTC, takotsubo cardiomyopathy; IHD, ischemic heart disease; HLD, hyperlipidemia; NSAID nonsteroidal anti-inflammatory drug; HTN, hypertension; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; DM, diabetes mellitus, ECMO, extracorporeal membrane oxygenation; R, Recovery; D, Death; SSS, sick sinus syndrome; EMB, endomyocardial biopsy; NR, Not reported.
Table 3. Adverse events after COVID-19 vaccination.

| Author, Year          | Country | Type of Study | Type of Vaccine | Number of Cases | Median Age | Gender | Patient Comorbidities                                                                 | Event             | Dose after Which Event Happened | Days after Vaccination Symptoms | Treatment | Outcome | Was EMB Done? If Yes, Findings                      |
|-----------------------|---------|---------------|-----------------|-----------------|------------|--------|--------------------------------------------------------------------------------------|-------------------|--------------------------------|---------------------------------|------------|----------|---------------------------------------------------|
| Rosner et al., 2021 [6] | USA     | Case series   | J&J: 1, Pfizer: 5, Moderna: 1 | 7               | 28, 39, 39, 24, 19, 20, 23 | 7 M     | NR                                                                                   | Myocarditis       | 1: 2 pts, 2: 5 pts               | 3 to 7 days                     | NA         | R        | 1/7: One patient underwent endomyocardial biopsy without pathological evidence of myocarditis |
| Kim et al., 2021 [7]  | USA     | Retrospective | Pfizer: 2, Moderna: 2 | 4               | 36, 23, 70, 24 | 3 M, 1 F | Pt 3: HTN, HLD, cigarette smoking; Others: None                                      | Myocarditis       | 2: 4 pts                        | 3, 5, 1, 2                     | R          | N        |                                                   |
| Larson et al., 2021 [8] | Case series | Moderna: 3, Pfizer: 5 | 8               | 22, 31, 40, 56, 26, 35, 21, 22 | 8 M     | NR                                                                                   | Myocarditis       | 1: 7 pts, 2: 1 pts               | 2-4 days                       | R          | N        |                                                   |
| Mansour et al., 2021 [9] | USA     | Case series   | Moderna: 2       | 2               | 25, 21       | 1 M, 1 F | NR                                                                                   | Myocarditis       | 2: 2 pts                        | 1: same day; 2: the next day    | Pt. 2 metoprolol                | R        | N        |                                                   |
| Lee et al., 2021 [23]  | Singapore | Case Series   | Pfizer: 3        | 3               | 70, 44, 73   | 3 F     | 1: Type 2 DM, HTN, HLD, prior CVA; 2: Mitral valve prolapse and mild mitral regurgitation; 3: HTN | Myocarditis       | 1: 3 pts                        | 1: same day; 2: same day; 3: same day | Pt. 1: PCI                   | R        | N        |                                                   |
| Habib et al., 2021 [24] | Qatar   | Case report   | Pfizer: 1        | 1               | 37          | M       | HTN                                                                                   | Myocarditis       | 2: 1                            | 3 days                          | LHC         | R        | N                                                  |
| Abu Mouch et al., 2021 [25] | Israel | Case series   | Pfizer: 6        | 6               | 1: 24, 2: 20, 3: 29, 4: 45, 5: 16, 6: 17 | 6 M     | NR                                                                                   | Myocarditis       | 1: 1 pt, 2: 5 pts               | 1: 72 h, 2: 24 h, 3: 48 h, 4: 16 days, 5: 24 h, 6: 72 h | NSAIDs and colchicine;          | R          | N        |                                                   |
| Chatterjee et al., 2021 [26] | India   | Case report   | Covishield: 1    | 1               | 63          | M       | NT                                                                                   | Myocardial infarction | 2                              | 48 h                           | Thrombolysis                | R        | N        |                                                   |
| Deb et al., 2021 [27]  | USA     | Case report   | Moderna: 1       | 1               | 67          | M       | NT                                                                                   | Acute myocardial injury | 2                              | 6 h                            | Diuretics                  | R        | N        |                                                   |
| Albert et al., 2021 [28] | USA     | Case report   | Moderna: 1       | 1               | 24          | M       | NT                                                                                   | Myocarditis       | 2                              | 24 h                           | Beta-blocker               | R        | N        |                                                   |
| Ammirati et al., 2021 [31] | USA     | Case report   | Pfizer: 1        | 1               | 56          | M       | NT                                                                                   | Acute myocarditis Type 1 Kounis syndrome | 2                              | 3 days                          | NA          | R        | N                                                  |
| Özdemir et al., 2021 [34] | Turkey  | Case report   | CoronaVac: 1     | 1               | 41          | F       | NR                                                                                   | Myocarditis       | 1                              | 15 min                          |                         | N        |                                                   |
Table 3. Cont.

| Author, Year                      | Country | Type of Study | Type of Vaccine | Number of Cases | Median Age | Gender | Patient Comorbidities | Event | Dose after Which Event Happened | Days after Vaccination Symptoms | Treatment | Outcome | Was EMB Done? | If Yes, Findings |
|-----------------------------------|---------|---------------|-----------------|-----------------|------------|--------|-----------------------|-------|--------------------------|-------------------------------|-----------|---------|---------------|-------------------|
| D’Angelo et al., 2021 [29]       | Italy   | Case report   | Pfizer: 1       | 1               | 30         | M      | NR                    | Myocarditis | 2                        | 72 h                          | N         |         |               |                   |
| Tajstra et al., 2021 [32]        | Poland  | Case report   | Pfizer: 1       | 1               | 86         | M      | Prostate cancer, Paroxysmal A.fib. | Acute MI | 1                        | 30 min                         | N         |         |               |                   |
| Montgomery et al., 2021 [22]     | USA     | Case series   | Pfizer: 7, Moderna:16 | 23         | Median age: 25 | 23 M   | NR                    | Myocarditis | 1: 3 pt; 2: 20 pts        | 4 days                         | N         |         |               |                   |
| Watad et al., 2021 [35]          | Israel  | Case series   | Pfizer: 2       | 2               | 48, 66     | 1 M, 1 F | Pt 1: HTN, HLD, HCM; Pt 2: Idiopathic pericarditis, anemia, DVT, spontaneous abortion in 1st trimester | 1: pericarditis; 2: pericarditis | 1: 2 pts; 1 pt had relapse after 2nd dose; 2: after 4 days for both events | 2 days                         | N         |         |               |                   |
| Watkins et al., 2021 [30]        | USA     | Case report   | Pfizer: 1       | 1               | 20         | M      | NR                    | Myocarditis | 1: TVD, MI, RCA occlusion; 2: LAD occlusion MI; 3: TVD, occlusion of posterolateral branch of RCA | 2                        | 2 days                         | N         |         |               |                   |
| Srinivasan et al., 2021 [33]     | India   | Case series   | Covishield: 3   | 3               | 46, 48, 75 | 2 M, 1 F | 1: DM, HTN, 2: DM, HTN, CAD; 3: NA | 1: 12 days; 2: 6 days; 3: 1 day | 2 pts; 1 pt |               | N         |         |               |                   |

TTC, takotsubo cardiomyopathy; IHD, Ischemic heart disease; HLD, hyperlipidemia; NSAID, nonsteroidal anti-inflammatory drug; HTN, hypertension; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; DM, diabetes mellitus, ECMO, extracorporeal membrane oxygenation; STEMI, ST elevation myocardial infarction; CAD, coronary artery disease; RCA, right coronary artery; LHC, left heart catheterization; R, Recovery; D, Death; EMB, endomyocardial biopsy; NR, not reported, A frib, atrial fibrillation.
### Table 4. Adverse events after Smallpox vaccination.

| Author, Year | Country | Type of Study | Number of Cases | Mean Age (Years) | Gender | Patient Comorbidities | Event | Dose after Which Event Happened | Days after Vaccination Symptoms | Treatment | Outcome | EMB(Y/N). If Y, findings |
|--------------|---------|---------------|-----------------|-----------------|--------|----------------------|-------|-------------------------------|--------------------------------|-----------|---------|--------------------------|
| Whitman et al., 2003 [36] | USA | Case Report | 1 | 29 | F | NR | Frequent episodes of trigeminy associated with symptoms of palpitations | 1 | 10 | Beta blocker | R | N |
| Lin et al., 2013 [55] | USA | Retrospective | 11 | NA | NA | NR | 4 pericarditis, 7 myopericarditis | 1 | 21 | Supportive | R | N |
| Engler et al., 2015 [37] | USA | Prospective Cohort | 5 | 4 M, 1 F | NR | | 4 pts myocarditis; 1 pt pericarditis | 1 | NA | Supportive | R | N |
| Eckart et al., 2004 [38] | USA | Systematic surveillance | 67 | 26.6 | 66 M, 1 F | NR | | 67 myocarditis | 1 | 10.4 | Supportive | 33 days after multiple vaccinations | Y, 1 fatality. Autopsy: eosinophilic epicardial inflammation; |
| Sarkissian et al., 2019 [39] | USA | Case Series | 6 | 23 | 6 M | NR | 2 cases: myocarditis; 4 cases: myopericarditis | 1 | 10.5 | Supportive | R | N |
| Saurina et al., 2003 [40] | USA | Case series | 1 | 20 | M | NR | Myocarditis | 1 | 8 | NSAIDs | R | N |
| Sharma et al., 2011 [41] | USA | Case Series | 2 | 34 | 2 M | NR | 1 case myocarditis, 1 case myopericarditis | 1 | 12 | NSAIDs | R | N |
| Sniadack et al., 2008 [42] | USA | Cohort prospective | 33 | 13 M, 20 F | NR | | 1: 4 pts; Revaccinee: 29 pts; | 11 | 11 M, 5 F | Supportive | R | N |
| Keinath et al., 2018 [43] | USA | Case study | 1 | 36 | M | NR | 1 myocarditis | 1 | 70 | Cardiostimulation, ICD placement, GDMT for HF | R | N |
| Halsell et al., 2003 [44] | USA | Case series | 18 | 26.5 | 18 M | NR | 18 cases of myopericarditis | 1 | 10.5 | Supportive | R | Y, eosinophilic infiltration |
| Mathews et al., 1974 [45] | England | Case report | 1 | 25 | M | NR | 1 myopericarditis | 1 | 14 | Hydrocortisone, Prednisone Dигоксин and furosemide | R | N |
| Eckart et al., 2005 [46] | USA | Retrospective | 62 | 30.2 | 61 M, 1 F | NR | 19% smokers | 1 | 1 | Supportive | R | Y, Pt1: no clear cellular infiltrate, Pt2: mild lymphocytic infiltrate; Pt3: eosinophilic infiltrate |
| Cangemi et al., 1958 [47] | USA | Case report | 1 | 56 | M | NR | | 62 cases of myocardiitis ACS:16 | 1 | 16 | Supportive | R | Y, mixed eosinophilic lymphocytic |
| Taylor et al., 2012 [48] | USA | Case report | 1 | 32 | M | Smoker | | 1 myopericarditis | 1 | 14 | Supportive | R | N |
| Murphy et al., 2003 [49] | USA | Case report | 1 | 29 | M | NR | | 1 myocarditis | 1 | 21 | NSAIDs, and pain control | R | N |
| Guerdan et al., 2004 [50] | USA | Case report | 1 | 26 | M | NR | | 1 myocarditis | 1 | 11 | | |

Note: ACS: acute coronary syndrome; DCM: dilated cardiomyopathy; GDMT: guideline-directed medical therapy; ICD: implantable cardioverter defibrillator; NSAIDs: nonsteroidal anti-inflammatory drugs; Supportive: supportive care; Y: death; NR: not reported; M: male; F: female; R: recovery; N: no event; N/A: not available; USA: United States of America; England: United Kingdom.
Table 4. Cont.

| Author, Year         | Country   | Type of Study | Number of Cases | Mean Age (Years) | Gender | Patient Comorbidities | Event                             | Dose after Which Event Happened | Days after Vaccination Symptoms | Treatment | Outcome | EMB(Y/N). If Y, findings |
|----------------------|-----------|---------------|-----------------|------------------|--------|----------------------|-----------------------------------|---------------------------------|---------------------------------|-----------|---------|------------------------|
| Docekal et al., 2019 [51] | USA       | Case report   | 1               | 20               | M      | NR                   | Recurrent epicardial V. tach      | 1                               | 28                              | EP ablations were attempted. R | N         |
| Jones et al., 1964 [52]  | USA       | Case report   | 1               | 39               | M      | NR                   | 1 myocarditis                    | 1                               | 11                              | Supportive D                      | D         |
| Dalgaard et al., 1954 [53] | Norway    | Case report   | 1               | 22               | M      | NR                   | 1 myocarditis                    | Revaccine                       | 8                               | Supportive D                      | D         |
| Bruner et al., 2014 [54] | USA       | Case report   | 1               | 27               | M      | NR                   | 1 myopericarditis                | 1                               | 14                              | Thrombolysis R                   | N         |

TTC, takotsubo cardiomyopathy; IHD, Ischemic heart disease; HLD, hyperlipidemia; NSAID, nonsteroidal anti-inflammatory drug; HTN, hypertension; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; DM, diabetes mellitus, ECMO, extracorporeal membrane oxygenation; STEMI, ST elevation myocardial infarction; CAD, coronary artery disease; RCA, right coronary artery; GDMT: Guideline directed medical therapy; HF: heart failure; EP: electrophysiology; R, recovery; D, death; M, male; F, female; EMB, endomyocardial biopsy; NR, Not reported; pts, patients.
Table 5. Adverse events after other vaccinations.

| Author, Year, Country | Type of Study | Number of Cases | Median Age | Gender | Patient Comorbidities | Event | Dose after Which Event Happened | Days after Vaccination Symptoms | Treatment | Outcome | EMB |
|-----------------------|--------------|----------------|------------|--------|-----------------------|-------|-------------------------------|---------------------------------|-----------|---------|-----|
| Makaryus et al., 2006 [56] USA | Case report | 1 | 71 | F | NR | Myocarditis | NA | Supportive: GDMT for HF | R | No | NA |
| Tawfik et al., 2017 [57] USA | Case report | 1 | 75 | F | NR | Pericardial effusion | 18 | Prednisone for 2 weeks tapered over 3 months | R | Yes; organized effusion containing hemorrhage, acute inflammation with reactive changes and mesothelial hyperplasia | NA |
| Boccara et al., 2001 [58] USA | Case report | 1 | 31 | M | NR | Myopericarditis | Re vaccine | NA | Aspirin | R |
| Clark et al., 2014 [60] USA | Case Report | 1 | 28 | M | Smoker | Myopericarditis | Re vaccine | 3 days | Colchicine and DAPT | R |
| Yamamoto et al., 2018 [59] Japan | Case report | 1 | 18 | M | NR | Myocarditis | Re-vaccine | NA | Steroids | R |
| Koutsaimanis et al., 1978 [61] England | Case Report | 1 | 40 | M | NR | MI, Anterior wall | 1 | 6 days | NA | R | N |
| Lyon et al., 1948 [62] Jerusalem | Case Report | 1 | 58 | M | NR | Myocarditis | 1 | Few weeks after 14 injections | Vitamin B complex and sedrena extract | R | N |

MI, myocardial infarction; CAD, coronary artery disease; GDMT: guideline directed medical therapy; HF: heart failure; EP: electrophysiology; R, recovery; D, death; M, male; F, female; DAPT: Dual antiplatelet therapy; EMB, endomyocardial biopsy; NR, not reported.
4. Discussion

Myocarditis is characterized by inflammation of the heart, and in resource-abundant countries, viral infections are the most frequently presumed cause of myocarditis [63]. Often pericarditis and myocarditis are observed in tandem; hence the term myopericarditis being recognized by the European Society of Cardiology (ESC). The annual incidence of myocarditis in the United States is estimated to be 1 to 10 per 100,000 of the population [44]. Vaccine-associated myocarditis is a rare event that was recognized as an adverse event after the mass revaccination against the smallpox virus began in military personnel. The new guidelines by ESC have now recognized inflammatory cardiomyopathy into four groups based on EMB results: inflammation-negative, virus-negative; inflammation-positive, virus-negative; inflammation-negative, virus-positive; and inflammation-positive, virus-positive [64]. Vaccine-associated cardiomyopathy usually falls into the virus-negative category. Characteristics of predisposed patients and treatment strategies remain to be defined.

The incidence of myopericarditis rose from 0.08 per 1000 to 0.11 per 1000 after the resumption of smallpox vaccination in 2002 [37]. Recent vaccination against the deadly COVID-19 virus has raised similar concerns of myopericarditis with an absolute rate of 1.7 per 1,000,000 vaccinated individuals as described by Husby et al. in a Denmark-based cohort study. However, these rates are much lower than the incidence rate described for viral myocarditis (10 to 22 per 100,000 individuals) [65]. Thus, there should be no vaccine hesitancy based on these cardiac AEs; however, physicians should be cautious about the development of these AEs, and care should not be delayed if suspicion arises.

Su et al.’s study on the VAERS database from 1990 to 2018 showed that most patients developing myopericarditis from vaccination were 19–49 years old, and 90% of this age group were male with symptom onset 8–14 days after vaccination [3]. The vaccines frequently associated with these AEs in order of frequency were smallpox, anthrax, typhoid, and inactivated influenza. Cardiac AEs from hepatitis B, zoster vaccine, hepatitis A, varicella, hemophilus, influenza, polio, and pneumococcal vaccine were also reported. We tried to study how these reactions differ with respect to the type of vaccine.

AEs following smallpox vaccination are the most studied among all vaccines. A prospective study by Engler et al. in military personnel saw an increased incidence of new-onset cardiac symptoms following smallpox and trivalent inactivated influenza with a relative risk difference of 16.11 between vaccinated and non-vaccinated populations [37]. Thus, vaccinia-associated inflammatory disease was defined as any cardiac inflammatory syndrome occurring within 30 days of vaccination without another identifiable cause [66]. Reif et al. described that the hyperactivation of inflammatory response from the variola virus in the smallpox vaccine is responsible for these AEs following smallpox vaccination. The study identified increased monocyte recruitment followed by upregulation of intercellular adhesion molecule 1 in patients developing adverse events. The activated macrophages then produce cytokine interleukin-10 (IL-10), which along with certain genotypes of IL-4, leads to increased production of granulocyte stimulating factor-3, a cytokine produced by activated T cells, macrophages, and endothelial cells to increase production of neutrophils for inflammatory reactions [67].

Influenza vaccination has been associated with a decrease in all-cause mortality in heart failure patients [68]. A literature search in 2017 described seven cases of pericarditis in patients above 60 years of age following influenza vaccination, as was seen in our analysis [12]. In a case series of 84 pericarditis cases by Zanettini et al., 23 cases were thought to be due to influenza vaccination in elderly females [18]. The mean time of symptom onset was seven days, as was seen in our analysis [12]. The mechanisms of systemic immunologic reactivity for pericarditis remain to be proven because of its rarity. Following influenza vaccination, there is a systemic inflammatory reaction, and it is postulated that the AEs, particularly TTC, may be due to this increased sympathetic discharge [15].

The first reports of AEs following COVID-19 vaccination came from Israel’s Health Ministry, which reported heart inflammation in cases who received the Pfizer vaccine [69]. Soon after, a CDC advisory committee on immunization practices identified a likely associ-
ation between the COVID-19 mRNA vaccines and cases of myocarditis and pericarditis [70]. Based on data from the VAERS, the CDC has estimated that the incidence of myocarditis after COVID-19 vaccination is 0.48 cases per 100,000 overall and 1.2 cases per 100,000 among vaccine recipients between the ages of 18 and 29 years. However, based on the study by Witberg et al. on the Israel database incidence of myocarditis, it was estimated that there were 2.13 cases per 100,000 vaccinated persons in the 42 days after the first vaccine dose [71]. It is important to consider these case reports within the broader context of the COVID-19 pandemic, which has caused tremendous morbidity and mortality throughout the world.

COVID-19 vaccination, especially AstraZeneca, was also found to be temporally related to thrombosis, but causality could not be proved; hence the vaccine was suspended [26,72]. Myocardial infarction (MI), in particular, is one of the most dreaded cardiac complications, as was seen in our included studies. The initial data from clinical trials by FDA briefing documents demonstrated that the incidence of MI was 0.02% and 0.03%, respectively, in the vaccine group. Later, a study on an elderly age group, comparing vaccinated and unvaccinated patients, did not show any significant increase in any cardiovascular events such as stroke or pulmonary embolisms [73].

As described earlier, these cardiac AEs are rare and different mechanisms have been proposed for these reactions, including molecular mimicry between immunogens in vaccines and human cells [74,75]. There is also the possibility of interaction between the encoded viral spike protein, antibodies generated by the host, and a yet undetermined cardiac protein in susceptible hosts [75]. Although these mechanisms for AEs are still enigmatic, a preponderance for male gender and younger age was observed in the VAERS database and our review [76]. The association of myocarditis with male sex and younger age could be attributed to sex hormones which may account for a more intense inflammatory response [77]. As suggested by experimental studies on myocarditis in mice, testosterone may be implicated in the inhibition of anti-inflammatory cells and the stimulation of immune responses by mRNA vaccine [78]. The presentation of symptoms within approximately two days of receiving a second dose (68% of patients) of mRNA vaccination also suggests an immune-mediated reaction in the host. Furthermore, cases of Type 1 Kounis syndrome have been described after inactivated COVID-19 vaccine, indicating an allergic reaction to a vaccine component [32].

According to 2012 ESC, cardiac magnetic resonance imaging (CMR) is the noninvasive gold standard method for the diagnosis of myocarditis [65]. CMR findings, including regional dysfunction, late gadolinium enhancement, and elevated native T1 and T2, have been used in many of these cases for myocarditis diagnosis following COVID-19 vaccination [7,9,22]. EMB, which is the gold standard, was performed on five patients with myocarditis after smallpox vaccination and in one patient after COVID-19 vaccination [65]. Three of them showed eosinophilic infiltrate. Yamamoto et al. also described biopsy-proven eosinophilic myocarditis following tetanus toxoid, which responded to high-dose corticosteroid treatment [59].

Specific guidelines for the management of vaccinia-associated myopericarditis have been outlined by the Department of Defense Vaccine Healthcare Center, and symptomatic patients should receive treatment with analgesics and/or NSAIDs as a first-line treatment [66]. Most cases in our study received colchicine and ibuprofen. In patients with persistent symptoms, steroids were advised [66]. The ESC guidelines advise immunosuppressive therapy for virus-negative myocarditis; however, the data are still unclear [79]. It is recommended that in patients refractory to standard therapy with no contraindications, treatment must be tailored on an individual basis [79]. Steroids were used for many patients in this review, which led to improvement.

5. Limitations

The review could not include all studies from the VAERS database. It was limited to full-text articles describing the patient and the cardiac AEs. The review also mostly
comprised of case reports, case series, and retrospective studies with few prospective studies. Therefore, there is a potential risk of bias, and the results should be interpreted with some caution. Given the rarity of these events and the retrospective nature of the events, it is not possible to estimate the relative risk of these AEs. Lastly, most of the studies did not provide all the required information, particularly about the results of cardiac testing and management.

6. Conclusions

Although vaccination remains a pivotal pillar of our healthcare to fight against some of the deadliest infections, understanding vaccine-associated cardiac adverse events will improve our healthcare delivery to this subpopulation. The incidence of cardiac AEs from vaccination remains much lower than cardiac AEs from other causes, but providers should be cautious of these AEs after vaccination.

**Author Contributions:** Drafting of the manuscript: K.P., S.S., G.D.R.-P.; Concept and design: K.P., G.D.R.-P.; Acquisition, analysis, or interpretation of data: K.P., S.S., G.D.R.-P.; Critical revision of the manuscript for important intellectual content: E.A.-S., P.S.; Supervision: E.A.-S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** No IRB approval required.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. VAERS. Vaccine Adverse Event Reporting System. Available online: https://vaers.hhs.gov/about.html (accessed on 15 January 2022).

2. Shimabukuro, T.T.; Nguyen, M.; Martin, D.; DeStefano, F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). *Vaccine* 2015, 33, 4908–4915. [CrossRef] [PubMed]

3. Su, J.R.; McNeil, M.M.; Welsh, K.J.; Marquez, P.L.; Ng, C.; Yan, M.; Cano, M.V. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018. *Vaccine* 2021, 39, 839–845. [CrossRef] [PubMed]

4. Kumar, A.; Singh, R.; Kaur, J.; Pandey, S.; Sharma, V.; Thakur, L.; Sati, S.; Mani, S.; Asthana, S.; Sharma, T.K.; et al. Wuhan to World: The COVID-19 Pandemic. *Front. Cell. Infect. Microbiol.* 2021, 11, 596201. [CrossRef] [PubMed]

5. Team MCVT. Available online: https://covid19.trackvaccines.org/agency/who/ (accessed on 24 November 2021).

6. Conclusions

Although vaccination remains a pivotal pillar of our healthcare to fight against some of the deadliest infections, understanding vaccine-associated cardiac adverse events will improve our healthcare delivery to this subpopulation. The incidence of cardiac AEs from vaccination remains much lower than cardiac AEs from other causes, but providers should be cautious of these AEs after vaccination.

**Author Contributions:** Drafting of the manuscript: K.P., S.S., G.D.R.-P.; Concept and design: K.P., G.D.R.-P.; Acquisition, analysis, or interpretation of data: K.P., S.S., G.D.R.-P.; Critical revision of the manuscript for important intellectual content: E.A.-S., P.S.; Supervision: E.A.-S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** No IRB approval required.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. VAERS. Vaccine Adverse Event Reporting System. Available online: https://vaers.hhs.gov/about.html (accessed on 15 January 2022).

2. Shimabukuro, T.T.; Nguyen, M.; Martin, D.; DeStefano, F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). *Vaccine* 2015, 33, 4908–4915. [CrossRef] [PubMed]

3. Su, J.R.; McNeil, M.M.; Welsh, K.J.; Marquez, P.L.; Ng, C.; Yan, M.; Cano, M.V. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018. *Vaccine* 2021, 39, 839–845. [CrossRef] [PubMed]

4. Kumar, A.; Singh, R.; Kaur, J.; Pandey, S.; Sharma, V.; Thakur, L.; Sati, S.; Mani, S.; Asthana, S.; Sharma, T.K.; et al. Wuhan to World: The COVID-19 Pandemic. *Front. Cell. Infect. Microbiol.* 2021, 11, 596201. [CrossRef] [PubMed]

5. Team MCVT. Available online: https://covid19.trackvaccines.org/agency/who/ (accessed on 24 November 2021).

6. Rosner, C.M.; Genovese, L.; Tehrani, B.N.; Atkins, M.; Bakhshi, H.; Chaudhri, S.; Damluji, A.A.; de Lemos, J.A.; Desai, S.S.; Emamnia, A.; et al. Myocarditis Temporally Associated With COVID-19 Vaccination. *Circulation* 2021, 144, 502–505. [CrossRef]

7. Kim, H.W.; Jenista, E.R.; Wendell, D.C.; Azevedo, C.F.; Campbell, M.J.; Darty, S.N.; Parker, M.A.; Kim, R.J. Patients with Acute Myocarditis Following mRNA COVID-19 Vaccination. *JAMA Cardiol.* 2021, 6, 1196. [CrossRef]

8. Larson, K.F.; Ammirati, E.; Adler, E.D.; Cooper, L.T., Jr.; De Ponti, F. Recurrence of pericarditis after influenza vaccination: A case report and review of the literature. *Clin. Neurol. Neurosurg.* 2019, 175, 1803–1805. [CrossRef] [PubMed]

9. Mansour, J.; Short, R.G.; Bhalla, S.; Woodard, P.K.; Verma, A.; Robinson, X.; Raptis, D.A. Acute myocarditis after a second dose of the mRNA COVID-19 vaccine: A report of two cases. *Clin. Imaging* 2021, 78, 247–249. [CrossRef]

10. Kao, C.-D.; Chen, J.-T.; Lin, K.-P.; Shan, D.-E.; Wu, Z.-A.; Liao, K.-K. Guillain-Barré syndrome coexisting with pericarditis or nephrotic syndrome after influenza vaccination. *Clin. Neurol. Neurosurg.* 2004, 106, 136–138. [CrossRef]

11. Kim, Y.J.; Bae, J.I.; Ryoo, S.M.; Kim, W.Y. Acute Fulminant Myocarditis Following Influenza Vaccination Requiring Extracorporeal Membrane Oxygenation. *Acute Crit. Care* 2019, 34, 165–169. [CrossRef]

12. Mei, R.; Raschi, E.; Poluzzi, E.; Dieminger, I.; De Ponti, F. Recurrence of pericarditis after influenza vaccination: A case report and review of the literature. *BMC Pharmacol. Toxicol.* 2018, 19, 20. [CrossRef]

13. De Meester, A.; Luwaert, R.; Chaudron, J.M. Symptomatic pericarditis after influenza vaccination: Report of two cases. *Chest* 2000, 117, 1803–1805. [CrossRef]

14. Santoro, F.; Ieva, R.; Ferraretti, A.; Carpeggiano, G.; Pappalardo, I.; De Gennaro, L.; Di Biase, M.; Brunetti, N.D. Tako-Tsubo cardiomypathy after influenza vaccination. *Int. J. Cardiol.* 2013, 167, e51–e52. [CrossRef]

15. Singh, K.; Marinelli, T.; Horowitz, J.D. Takotsubo cardiomyopathy after anti-influenza vaccination: Catecholaminergic effects of immune system. *Am. J. Emerg. Med.* 2013, 31, e1–e4. [CrossRef]

16. Streifler, J.J.; Dux, S.; Garty, M.; Rosenfeld, J.B. Recurrent pericarditis: A rare complication of influenza vaccination. *Br. Med. J.* 1981, 283, 526–527. [CrossRef]

17. Cheng, M.P.; Kozoriz, M.G.; Ahmadi, A.A.; Kelsall, J.; Paquette, K.; Omrot, J.M. Post-vaccination myositis and myocarditis in a previously healthy male. *Allergy Asthma Clin. Immunol.* 2016, 12, 6. [CrossRef]
18. Zanettini, M.T.; Zanettini, J.O.; Zanettini, J.P. Pericarditis. Series of 84 consecutive cases. *Arq. Bras. Cardiol.* 2004, 82, 360–369. [CrossRef]

19. Godreuil, S.; Delhaume, O.; Besset-Prat, L.; Blayac, J.P.; Peyriere, H.; Bonnet, P. Acute haemorrhagic pericarditis following influenza vaccination. *Presse Med.* 2003, 32, 258–259.

20. Wiley. Available online: https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.12252 (accessed on 24 November 2021).

21. Lee, E.; Chew, N.W.S.; Ng, P.; Yeo, T.J. Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. *JQM* 2021, 114, hcb231. [CrossRef]

22. Montgomery, J.; Ryan, M.; Engler, R.; Hoffman, D.; McClennathan, B.; Collins, L.; Loram, D.; Hrnčir, D.; Herring, K.; Platerz, M.; et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiol.* 2021, 6, 120. [CrossRef]

23. Lee, E.; Chew, N.W.S.; Ng, P.; Yeo, T.J. A spectrum of cardiac manifestations post Pfizer-BioNTech COVID-19 vaccination. *JQM* 2021, 114, 661–662. [CrossRef]

24. Habib, M.B.; Hamamyh, T.; Elyas, A.; Altermanini, M.; Elhassan, M. Acute myocarditis following administration of BNT162b2 vaccine. *IDCases* 2021, 25, e01197. [CrossRef]

25. Mouch, S.A.; Roguin, A.; Hellou, E.; Ishai, A.; Shoshan, U.; Mahamid, L.; Zoabi, M.; Aisman, M.; Goldschmid, N.; Yanay, N.B. Myocarditis following COVID-19 mRNA vaccination. *Vaccine* 2021, 39, 3790–3793. [CrossRef]

26. Chatterjee, S.; Ojha, U.K.; Vardhan, B.; Tiwari, A. Myocarditis secondary to smallpox vaccination. *BMJ Case Rep.* 2021, 10558–10556. [CrossRef]

27. Deb, A.; Abdelmalek, J.; Iwuji, K.; Nugent, K. Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. *J. Prim. Care Community Health* 2021, 12, 21501327211029230. [CrossRef]

28. Albert, E.; Aurigemma, G.; Saucedo, J.; Gerson, D.S. Myocarditis following COVID-19 vaccination. *Am. J. Emerg. Med.* 2021, 50, 815.e1–815.e2. [CrossRef]

29. Ammirati, E.; Cavallotti, C.; Milazzo, A.; Pedrotti, P.; Soriano, F.; Schroeder, J.W.; Morici, N.; Giannattasio, C.; Frigerio, M.; Metra, M.; et al. Temporal Relation Between Second Dose BNT162b2 mRNA Covid-19 Vaccine and Cardiac involvement in a Patient with Previous SARS-COV-2 Infection. *Int. J. Cardiol. Heart Vasc.* 2021, vol.34, 100774.

30. Tajstra, M.; Jaroszewicz, J.; Gasior, M. Acute Coronary Thrombosis After Vaccination for COVID-19. *JACC Cardiovasc. Interv.* 2021, 14, e103–e104. [CrossRef]

31. Srinivasan, K.N.; Sathyamurthy, I.; Neelagandan, M. Relation between COVID-19 vaccination and myocardial infarction—Causal or coincidental? *IJH Cardiovasc. Case Rep.* 2021, 5, 71–74. [CrossRef]

32. Özdemir, İ.H.; Özlek, B.; Özen, M.B.; Gündüz, R.; Bayturan, Ö. Type 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine. *Clin. Immunol.* 2021, 2021, 61, e71–e76. [CrossRef] [PubMed]

33. Watad, A.; De Marco, G.; Mahajna, H.; Druyan, A.; Eltity, M.; Hijazi, N.; Haddad, A.; Elias, M.; Zisman, D.; Naffaa, M.E.; et al. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. *Vaccines* 2021, 9, 435. [CrossRef] [PubMed]

34. Eckart, R.E.; Love, S.S.; Atwood, J.E.; Arness, M.K.; Cassimatis, D.C.; Campbell, C.L.; Boyd, S.Y.; Murphy, J.G.; Swerdlow, D.L.; et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. *QJM* 2021, 114, 258–259. [CrossRef] [PubMed]

35. Watad, A.; De Marco, G.; Mahajna, H.; Druyan, A.; Eltity, M.; Hijazi, N.; Haddad, A.; Elias, M.; Zisman, D.; Naffaa, M.E.; et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. *JAMA Cardiol.* 2021, 6, 120. [CrossRef]

36. Timothy, J.; Whitman, M.; Ferguson, A.; Catherine, F.; Decker, A. Cardiac Dysrhythmia following Smallpox Vaccination. *Clin. Infect. Dis.* 2003, 37, 1579–1580. [CrossRef]

37. Engler, R.J.; Nelson, M.R.; Collins, L.C., Jr.; Spooner, C.; Hemann, B.A.; Gibbs, B.T.; Atwood, J.E.; Howard, R.S.; Chang, A.S.; Cruser, D.L.; et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. *PLoS ONE.* 2015, 10, e0118283. [CrossRef] [PubMed]

38. Cruser, D.L.; et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. *Plos ONE.* 2015, 10, e0118283. [CrossRef] [PubMed]

39. Eckart, R.E.; Love, S.S.; Arness, M.K.; Cassimatis, D.C.; Campbell, C.L.; Boyd, S.Y.; Murphy, J.G.; Swerdlow, D.L.; Collins, L.C.; et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. *J. Am. Coll. Cardiol.* 2004, 44, 201–205. [CrossRef]

40. Sarkisian, S.A.; Hand, G.; Rivera, VM.; Smith, M.; Miller, J.A. A Case Series of Smallpox Vaccination-Associated Myopericarditis: Effects on Safety and Readiness of the Active Duty Soldier. *Mil. Med.* 2019, 184, e280–e283. [CrossRef]

41. Saurina, G.; Shirazi, S.; Lane, J.M.; Daniel, B.; Di Eugenia, L. Myocarditis after Smallpox Vaccination: A Case Report. *Clin. Infect. Dis.* 2003, 37, 145–146. [CrossRef]

42. Sharma, U.; Tak, T. A report of 2 cases of myopericarditis after Vaccinia virus (smallpox) immunization. *WMJ* 2011, 110, 291–294.

43. Keinath, K.; Church, T.; Kurth, B.; Hulten, E. Myocarditis secondary to smallpox vaccination. *BMJ Case Rep.* 2018, 2018, bcr–2017–223523. [CrossRef]

44. Halsell, J.S.; Riddle, J.R.; Atwood, J.E.; Gardner, P.; Shope, R.; Poland, G.A.; Gray, G.C.; Ostroff, S.; Eckart, R.E.; Hospenthal, D.R.; et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. *JAMA* 2003, 289, 3283–3289. [CrossRef]
45. Matthews, A.W.; Griffiths, J.D. Post-vaccinal pericarditis and myocarditis. Br. Heart J. 1974, 36, 1043–1045. [CrossRef]

46. Eckart, R.E.; Shry, E.A.; Jones SOT Atwood, J.E.; Grabenstein, J.D. Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age. Am. J. Cardiol. 2005, 95, 1252–1255.

47. Cangemi, V.F. Acute pericarditis after smallpox vaccination. N. Engl. J. Med. 1958, 258, 1257–1259. [CrossRef]

48. Taylor, C.L.; Eckart, R.E. Chest pain, ST elevation, and positive cardiac enzymes in an austere environment: Differentiating smallpox vaccination-mediated myocarditis and acute coronary syndrome in Operation Iraqi Freedom. J. Emerg. Med. 2012, 42, 267–270. [CrossRef]

49. Murphy, J.G.; Wright, R.S.; Bruce, G.K.; Baddour, L.M.; Farrell, W.D.; Kita, H.; Cooper, L.T. Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet 2003, 362, 1378–1380. [CrossRef]

50. Guerdan, B.R.; Shamway, G.J. Case Report: A Presumptive Case of Vaccinia Myocarditis. Mil. Med. 2004, 169, 866–867. [CrossRef]

51. Docekal, J.W.; Francisco, G.; Lee, J.C. Recurrent epicardial ventricular tachycardia following smallpox vaccination. Heart Rhythm Case Rep. 2018, 5, 6–9. [CrossRef]

52. Finlay-Jones, I.R. Fatal myocarditis after vaccination against smallpox—Report of a case. N. Engl. J. Med. 1964, 270, 41–42. [CrossRef]

53. Dalgaard, J.B. Fatal myocarditis following smallpox vaccination. Am. Heart J. 1957, 54, 156–157. [CrossRef]

54. Bruner, D.I.; Butler, B.S. Smallpox vaccination-associated myopericarditis is more common with the newest smallpox vaccine. J. Emerg. Med. 2014, 46, e85–e87. [CrossRef]

55. Lin, A.H.; Phan, H.A.; Barthel, R.V.; Maisel, A.S.; Crum-Cianflone, N.F.; Maves, R.C.; Nayak, K.R. Myopericarditis and pericarditis in the deployed military member: A retrospective series. Mil. Med. 2013, 178, 18–20. [CrossRef]

56. Makaryus, A.N.; Revere, D.J.; Steinberg, B. Recurrent reversible dilated cardiomypathy secondary to viral and streptococcal pneumonia vaccine-associated myocarditis. Cardiol. Rev. 2006, 14, e1–e4. [CrossRef] [PubMed]

57. Tawfik, P.; Gertner, E.; McEvoy, C.E. Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: A case report. J. Med. Case Rep. 2017, 11, 142. [CrossRef] [PubMed]

58. Boccara, F.; Benhaiem-Sigaux, N.; Cohen, A. Acute myopericarditis after diphtheria, tetanus, and polio vaccination. Chest 2001, 120, 671–672. [CrossRef] [PubMed]

59. Yamamoto, H.; Hashimoto, T.; Ohta-Ogo, K.; Ishibashi-Ueda, H.; Imanaka-Yoshida, K.; Hiroe, M.; Yokochi, T. A case of biopsy-proven eosinophilic myocarditis related to tetanus toxoid immunization. Cardiovasc. Pathol. 2018, 37, 54–57. [PubMed]

60. Clark, A.L.; Boroujerdi-Rad, L. Acute myopericarditis after tetanus, diphtheria, and pertussis vaccination in a healthy adult. J. Gen. Intern. Med. 2014, 29, S298.

61. Koutsaimanis, K.G.; Rée, G.H. Possible association of myocardial infarction and active immunization. N. Engl. J. Med. 1978, 299, 153–154.

62. Karger. Available online: https://wwwkargercom/Article/Pdf/167026 (accessed on 15 December 2021).

63. Seferovitch, P.M.; Tsutsui, H.; McNamara, D.M.; Ristíc, A.D.; Basso, C.; Bozkurt, B.; Jr, L.T.C.; Filippatos, G.; Ide, T.; Inomata, T.; et al. Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur. J. Heart Fail. 2021, 23, 854–871. [CrossRef]

64. Tschöpe, C.; Ammirati, E.; Bozkurt, B.; Caforio, A.L.P.; Cooper, L.T.; Felix, S.B.; Hare, J.M.; Heidecker, B.; Heymans, S.; Hübner, N.; et al. Myocarditis and inflammatory cardiomypathy: Current evidence and future directions. Nat. Rev. Cardiol. 2021, 18, 169–193. [CrossRef]

65. Olejniczak, M.; Schwartz, M.; Webber, E.; Shaffer, A.; Perry, T.E. Viral Myocarditis-Incidence, Diagnosis and Management. J. Cardiothorac. Vasc. Anesth. 2020, 34, 1591–1601. [CrossRef]

66. Cassimatis, D.C.; Atwood, J.E.; Engler, R.M.; Linz, P.E.; Grabenstein, J.D.; Veralis, M.N. Smallpox vaccination and myopericarditis: A clinical review. J. Am. Coll. Cardiol. 2004, 43, 1503–1510. [CrossRef]

67. Reif, D.M.; Motsinger-Reif, A.A.; McKinney, B.A.; Rock, M.T.; Crowe, J.E.; Moore, J.H. Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination. Genes Immun. 2009, 10, 112–119. [CrossRef]

68. Rodrigues, B.S.; Alves, M.; Duarte, G.S.; Costa, J.; Pinto, F.J.; Caldeira, D. The impact of influenza vaccination in patients with cardiovascular disease: An overview of systematic reviews. Trends Cardiovasc. Med. 2021, 31, 315–320. [CrossRef]

69. Reuters. Israel Examining Heart Inflammation Cases in People Who Received Pfizer COVID Shot. Available online: https://www.reuters.com/world/middle-east/israel-examining-heart-inflammation-cases-people-who-received-pfizer-covid-shot-2021-04-25/ (accessed on 15 January 2022).

70. Hannah, G.; Rosenblum, M. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices—United States, July 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1094.

71. Witberg, G.; Barda, N.; Hoss, S.; Richter, I.; Wiessman, M.; Aviv, Y.; Grinberg, T.; Auster, O.; Dagan, N.; Balicer, R.D.; et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N. Engl. J. Med. 2021, 385, 2132–2139. [CrossRef]

72. Wise, J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 2021, 372, n699. [CrossRef]
73. Jabagi, M.J.; Botton, J.; Bertrand, M.; Weill, A.; Farrington, P.; Zureik, M.; Dray-Spira, R. Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. *JAMA* 2022, 327, 80–82. [CrossRef]

74. Bozkurt, B.; Kamat, I.; Hotez, P.J. Myocarditis With COVID-19 mRNA Vaccines. *Circulation* 2021, 144, 471–484. [CrossRef]

75. Vojdani, A.; Kharrazian, D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. *Clin. Immunol.* 2020, 217, 108480. [CrossRef]

76. Hajjo, R.; Sabbah, D.A.; Bardaweeel, S.K.; Tropsha, A. Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. *Vaccines* 2021, 9, 1186. [CrossRef]

77. Lazaros, G.; Klein, A.L.; Hatziantoniou, S.; Tsioufis, C.; Tsakris, A.; Anastassopoulou, C. The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism. *Vaccine* 2021, 39, 4925–4927. [CrossRef]

78. Huber, S.A.; Pfaeffle, B. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. *J. Virol.* 1994, 68, 5126–5132. [CrossRef]

79. Caforio, A.L.P.; Pankuweit, S.; Arbustini, E.; Basso, C.; Gimeno-Blanes, J.; Felix, S.B.; Fu, M.; Heliö, T.; Heymans, S.; Jahns, R.; et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur. Heart J.* 2013, 34, 2636–2648. [CrossRef]